Keros Therapeutics’ (KROS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $100.00 target price on the stock.

KROS has been the topic of a number of other reports. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating on the stock. Wedbush raised shares of Keros Therapeutics to a “strong-buy” rating in a report on Monday, November 4th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, Bank of America reduced their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Price Performance

Shares of KROS opened at $67.91 on Thursday. The firm has a fifty day moving average price of $58.19 and a 200 day moving average price of $52.16. The stock has a market cap of $2.55 billion, a PE ratio of -13.03 and a beta of 1.23. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 45.13%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share. As a group, equities analysts expect that Keros Therapeutics will post -4.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KROS. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics during the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics in the second quarter valued at $128,000. Finally, Ameritas Investment Partners Inc. increased its position in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.